MVA-Nsmut HCV vaccine / GSK - LARVOL DELTA

Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans. (PubMed, NPJ Vaccines) - "In this study, healthy volunteers received chimpanzee-derived adenovirus-3 and MVA vaccines encoding the non-structural region of hepatitis C virus (ChAd3-NSmut/MVA-NSmut) 8 weeks apart...Overall, we show that following Ad/MVA prime-boost vaccination reboosting is most effective after a prolonged interval and is productive with MVA alone. Importantly, we also show that a ten-fold lower dose of MVA is as potent in humans as the standard dose."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Oncology

Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans. (PubMed, NPJ Vaccines) - "In this study, healthy volunteers received chimpanzee-derived adenovirus-3 and MVA vaccines encoding the non-structural region of hepatitis C virus (ChAd3-NSmut/MVA-NSmut) 8 weeks apart...Overall, we show that following Ad/MVA prime-boost vaccination reboosting is most effective after a prolonged interval and is productive with MVA alone. Importantly, we also show that a ten-fold lower dose of MVA is as potent in humans as the standard dose."

Journal • Hepatitis C Virus • Hepatology • Infectious Disease • Oncology

Co-administration of serologically distinct adenoviral vectors for HCV and HIV-1 prevention (AGW 2016) - "Material and Methods: Thirty-two healthy volunteers were recruited in a Phase-I (EU Fp7 funded) clinical trial and sequentially enrolled into 3 groups: Group 1 (n = 8) received HCV vaccines: AdCh3NSmut1 [2.5x1010 vp] and MVA.NSmut [2x108 pfu] at weeks 0 and 8, respectively. Co-administration of serologically distinct adenoviral vectors encoding HCV and HIV-1 immunogens in a heterologous prime-boost regimen can be safety administered and induce broad and high magnitude T cell responses. This provides a novel strategy for the prevention of multiple pathogens in the same individual."

Biosimilar • Gene Therapies • Hepatitis C Virus • Immunology

A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: University of Oxford

New P1 trial • Biosimilar • Hepatitis C Virus • Immunology • Inflammation

A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection. (PubMed, Front Immunol) - P1; " We conducted a phase I trial in which 33 healthy volunteers were sequentially enrolled and vaccinated via the intramuscular route as follows: 9 received ChAd3-NSmut [2.5 × 10 vp] and MVA-NSmut [2 × 10 pfu] at weeks 0 and 8, respectively; 8 received ChAdV63.HIVconsv [5 × 10 vp] and MVA.HIVconsv [2 × 10 pfu] at the same interval; 16 were co-primed with ChAd3-NSmut [2.5 × 10 vp] and ChAdV63.HIVconsv [5 × 10 vp] followed at week 8 by MVA-NSmut and MVA.HIVconsv [both 1 × 10 pfu]...This provides a novel strategy for targeting these viruses simultaneously and for other pathogens that affect the same populations. Clinical trial registration: https://clinicaltrials.gov, identifier: NCT02362217."

Journal